Clinical and biological implications of driver mutations in myelodysplastic syndromes.

نویسندگان

  • Elli Papaemmanuil
  • Moritz Gerstung
  • Luca Malcovati
  • Sudhir Tauro
  • Gunes Gundem
  • Peter Van Loo
  • Chris J Yoon
  • Peter Ellis
  • David C Wedge
  • Andrea Pellagatti
  • Adam Shlien
  • Michael John Groves
  • Simon A Forbes
  • Keiran Raine
  • Jon Hinton
  • Laura J Mudie
  • Stuart McLaren
  • Claire Hardy
  • Calli Latimer
  • Matteo G Della Porta
  • Sarah O'Meara
  • Ilaria Ambaglio
  • Anna Galli
  • Adam P Butler
  • Gunilla Walldin
  • Jon W Teague
  • Lynn Quek
  • Alex Sternberg
  • Carlo Gambacorti-Passerini
  • Nicholas C P Cross
  • Anthony R Green
  • Jacqueline Boultwood
  • Paresh Vyas
  • Eva Hellstrom-Lindberg
  • David Bowen
  • Mario Cazzola
  • Michael R Stratton
  • Peter J Campbell
چکیده

Myelodysplastic syndromes (MDS) are a heterogeneous group of chronic hematological malignancies characterized by dysplasia, ineffective hematopoiesis and a variable risk of progression to acute myeloid leukemia. Sequencing of MDS genomes has identified mutations in genes implicated in RNA splicing, DNA modification, chromatin regulation, and cell signaling. We sequenced 111 genes across 738 patients with MDS or closely related neoplasms (including chronic myelomonocytic leukemia and MDS-myeloproliferative neoplasms) to explore the role of acquired mutations in MDS biology and clinical phenotype. Seventy-eight percent of patients had 1 or more oncogenic mutations. We identify complex patterns of pairwise association between genes, indicative of epistatic interactions involving components of the spliceosome machinery and epigenetic modifiers. Coupled with inferences on subclonal mutations, these data suggest a hypothesis of genetic "predestination," in which early driver mutations, typically affecting genes involved in RNA splicing, dictate future trajectories of disease evolution with distinct clinical phenotypes. Driver mutations had equivalent prognostic significance, whether clonal or subclonal, and leukemia-free survival deteriorated steadily as numbers of driver mutations increased. Thus, analysis of oncogenic mutations in large, well-characterized cohorts of patients illustrates the interconnections between the cancer genome and disease biology, with considerable potential for clinical application.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.

An increasingly complete compendium of recurrently mutated genes in myelodysplastic syndromes (MDS) has been defined, and the application of massively parallel sequencing to identify mutations in clinical practice now promises to improve the care of patients with this disease. More than 25 recurrent MDS-associated somatic mutations have been identified, involving biologic pathways as diverse as...

متن کامل

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

The prognostic and predictive value of sequencing analysis in myelodysplastic syndromes (MDS) has not been fully integrated into clinical practice. We performed whole exome sequencing (WES) of bone marrow samples from 83 patients with MDS and 31 with MDS/MPN identifying 218 driver mutations in 31 genes in 98 (86%) patients. A total of 65 (57%) patients received therapy with hypomethylating agen...

متن کامل

Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing

Myelodysplastic syndromes (MDS) are a group of myeloid hematological malignancies, with a high risk of progression to acute myeloid leukemia (AML). To explore the role of acquired mutations in MDS, 111 MDS-associated genes were screened using next-generation sequencing (NGS), in 125 patients. One or more mutations were detected in 84% of the patients. Some gene mutations are specific for MDS an...

متن کامل

Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies

Myelodysplastic syndromes (MDS) are defined as stem cell disorders caused by various gene abnormalities. Recent analysis using next-generation sequencing has provided great advances in identifying relationships between gene mutations and clinical phenotypes of MDS. Gene mutations affecting RNA splicing machinery, DNA methylation, histone modifications, transcription factors, signal transduction...

متن کامل

The genetic basis of myelodysplasia and its clinical relevance.

Myelodysplasia is a diagnostic feature of myelodysplastic syndromes (MDSs) but is also found in other myeloid neoplasms. Its molecular basis has been recently elucidated by means of massive parallel sequencing studies. About 90% of MDS patients carry ≥1 oncogenic mutations, and two thirds of them are found in individuals with a normal karyotype. Driver mutant genes include those of RNA splicing...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Blood

دوره 122 22  شماره 

صفحات  -

تاریخ انتشار 2013